DIABETES MELLITUS–ASSOCIATED CHRONIC KIDNEY DISEASE: FROM PATHOPHYSIOLOGY TO CLINICAL MANAGEMENT

Panjiyev Jonibek Abdumajidovich

Authors

Panjiyev Jonibek Abdumajidovich Department of Preclinic Sciences of the Asian International University, Bukhara, Uzbekistan

Keywords:

Chronic kidney disease, diabetes mellitus, diabetic nephropathy

Abstract

Chronic kidney disease (CKD) is increasingly acknowledged as a major global public health concern, affecting approximately 10% to 15% of the global population. Diabetes mellitus represents the predominant cause of end-stage renal disease worldwide. Currently, more than 422 million adults globally are living with diabetes mellitus, and nearly 40% of these individuals are expected to develop CKD during their lifetime. Chronic kidney disease frequently occurs as both a complication and a comorbid condition in patients with diabetes mellitus. The management of individuals with diabetes and CKD, including strict regulation of glycemic levels and blood pressure, has historically been similar in patients with type 1 and type 2 diabetes. However, emerging therapeutic targets have demonstrated encouraging outcomes and may provide more individualized and disease-specific treatment strategies for both type 1 and type 2 diabetes patients.

References

Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414: 813–820. https://doi.org/10.1038/414813a

Cherney DZ, Perkins BA, Soleymanlou N, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 2014; 129: 587–597. https://doi.org/10.1161/CIRCULATIONAHA.113.005081

Fioretto P, Mauer M. Diabetic nephropathy: challenges in pathologic classification. Nature Reviews Nephrology 2010; 6: 508–510. https://doi.org/10.1038/nrneph.2010.96

Fioretto P, Mauer M, Brocco E, et al. Patterns of renal injury in NIDDM patients with microalbuminuria. Diabetologia 1996; 39: 1569–1576. https://doi.org/10.1007/s001250050616

Gerich JE. Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabetic Medicine 2010; 27: 136–142. https://doi.org/10.1111/j.1464-5491.2009.02894.x

Hostetter TH, Olson JL, Rennke HG, Venkatachalam MA, Brenner BM. Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. American Journal of Physiology 1981; 241: F85–F93. https://doi.org/10.1152/ajprenal.1981.241.1.F85

Inoguchi T, Li P, Umeda F, et al. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C–dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes 2000; 49: 1939–1945. https://doi.org/10.2337/diabetes.49.11.1939

KDIGO. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. Kidney International 2020; 98: 1–115.

King P, Peacock I, Donnelly R. The UK prospective diabetes study (UKPDS): clinical and therapeutic implications for type 2 diabetes. British Journal of Clinical Pharmacology 1999; 48: 643–648. https://doi.org/10.1046/j.1365-2125.1999.00092.x

Krolewski AS, Niewczas MA, Skupien J, et al. Early progressive renal decline precedes the onset of microalbuminuria and its progression to macroalbuminuria. Diabetes Care 2014; 37: 226–234. https://doi.org/10.2337/dc13-0985

Mathisen UD, Melsom T, Ingebretsen OC, et al. Estimated GFR associates with cardiovascular risk factors independently of measured GFR. Journal of the American Society of Nephrology 2011; 22: 927–937. https://doi.org/10.1681/ASN.2010050479

Mogensen CE. How to protect the kidney in diabetic patients: with special reference to IDDM. Diabetes 1997; 46 (Suppl 2): S104–S111. https://doi.org/10.2337/diab.46.2.s104

Sharma SG, Bomback AS, Radhakrishnan J, et al. The modern spectrum of renal biopsy findings in patients with diabetes. Clinical Journal of the American Society of Nephrology 2013; 8: 1718–1724. https://doi.org/10.2215/CJN.02510213

Tong X, Yu Q, Ankawi G, et al. Insights into the role of renal biopsy in patients with T2DM: a literature review of global renal biopsy results. Diabetes Therapy 2020; 11: 1983–1999. https://doi.org/10.1007/s13300-020-00888-w

Tervaert TW, Mooyaart AL, Amann K, et al. Pathologic classification of diabetic nephropathy. Journal of the American Society of Nephrology 2010; 21: 556–563. https://doi.org/10.1681/ASN.2010010010

Umanath K, Lewis JB. Update on diabetic nephropathy: core curriculum 2018. American Journal of Kidney Diseases 2018; 71: 884–895. https://doi.org/10.1053/j.ajkd.2017.10.026

United States Renal Data System. 2019 USRDS Annual Data Report: Epidemiology of Kidney Disease in the United States. Bethesda, MD: NIH, NIDDK; 2019.

American Diabetes Association. Classification and diagnosis of diabetes: standards of medical care in diabetes—2019. Diabetes Care 2019; 42 (Suppl 1): S13–S28. https://doi.org/10.2337/dc19-S002

American Diabetes Association. Glycemic targets: standards of medical care in diabetes—2020. Diabetes Care 2020; 43 (Suppl 1): S66–S76. https://doi.org/10.2337/dc20-S006